Download Files:
BJE6-106
$350 – $2,800
Products Details
Product Description
– BJE6-106 (B106) is a potent, selective 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis. BJE6-106 (B106) possesses tumor-specific effect.
Web ID
– HY-117800
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C26H23NO2
References
– [1]Takashima A,et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9(4):1003-14.
CAS Number
– 1564249-38-2
Molecular Weight
– 381.47
Compound Purity
– 99.93
SMILES
– O=CC1=C2C(C=CC(C)(C)O2)=CC(CCN3C4=C(C5=C3C=CC=C5)C=CC=C4)=C1
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Apoptosis;PKC
Isoform
– PKCα;PKCδ
Pathway
– Apoptosis;Epigenetics;TGF-beta/Smad
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
